Boehringer Ingelheim Pharmaceuticals Inc

3 of its medicines lose their last listed patent or exclusivity between January 1, 2026 and December 31, 2027.

March 7, 2026Pradaxadabigatran etexilate mesylate
July 19, 2026Spirivatiotropium bromide
January 19, 2027Striverdi Respimatolodaterol hydrochloride

Dates are the patent and exclusivity end dates listed in the FDA's Orange Book, in its data up to October 9, 2026. Patents can be extended, challenged in court or settled, so a generic may come earlier, later or not at all. This is not legal or medical advice.

About the data·Privacy·Credits